() Replimune NEXT GENERATION ONCOLYTIC IMMUNOTHERAPY NEXT-GENERATION ONCOLYTIC August 2020 Safe harbor Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the advancement of our clinical trials, patient enrollments in our existing and planned clinical trials and th ...

NEXT GENERATION ONCOLYTIC IMMUNOTHERAPY NEXT-GENERATION ONCOLYTIC IMMUNOTHERAPY Investor JP Morgan Presentation January 2020 Safe harbor 2 Any statements contained herein that are not statements of historical facts may be deemed to be forwardlooking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our cash runway, our advancement of our clinical trials, the results of our ...

NEXT GENERATION ONCOLYTIC IMMUNOTHERAPY NEXT-GENERATION ONCOLYTIC IMMUNOTHERAPY December 2019 Piper Jaffray 31st Annual Healthcare Conference Safe harbor 2 Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations about our use of cash, our advancement o ...

NEXT GENERATION ONCOLYTIC IMMUNOTHERAPY NEXT-GENERATION ONCOLYTIC IMMUNOTHERAPY SITC Investor Event Presentation November 8th 2019 Safe harbor 2 Any statements contained herein that are not statements of historical facts may be deemed to be forwardlooking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations about our use of cash, our advancement of our clinic ...

NEXT GENERATION ONCOLYTIC IMMUNOTHERAPY NEXT-GENERATION ONCOLYTIC IMMUNOTHERAPY 37th Annual JPMorgan Healthcare Conference Safe harbor 2 Any statements contained herein that are not statements of historical facts may be deemed to be forwardlooking statements which are subject to risks and uncertainties. Accordingly, actual outcomes or results may differ materially from those indicated in these statements for many reasons, including, without limitation, risks associated with our collaborations, our clinical ...